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According to the definitions of the First
International Consultation on erectile dysfunc-
tion (ED), co-sponsored by the World Health
Organization (WHO), ED is considered “the
consistent or recurrent inability to attain
and/or to maintain a penile erection sufﬁcient
for sexual performance” (Jardin et al. 2000).
Although ED is a benign disorder, it is related
to physical and psychological health, and it has
a notable impact on the quality of life of suffer-
ers and their families (Wespes et al. 2002). 
Aging is the most common risk factor
associated with ED. Therefore, age-related
factors, including hormonal derangement,
diabetes mellitus, neural damage from surgery,
side effects of drug, radiation therapy, and
psychogenic factors, are the most frequently
cited causes of ED (Araujo et al. 1998; Wein
and van Arsdalen 1988). Of the sex hormone
levels, the changes in free testosterone corre-
late most closely with aging and have the clos-
est correlation with sexual activity (Ahn et al.
2002). Androgens have been suggested to be
essential in the maintenance of libido and
important in regulating penile smooth muscle
function in men (Salonia et al. 2003). In ani-
mal models, androgens can regulate the
expression and activity of nitric oxide synthase
(NOS) isoforms in the corpus cavernosum
(Marin et al. 1999; Park et al. 1999; Shen et al.
2000). Nitric oxide (NO) was considered to
mediate relaxation of the vascular smooth mus-
cle of the resistance arteries of the corpus caver-
nosum and the trabeculae to facilitate penile
erection (Andersson and Wagner 1995;
Burnett et al. 1992; Moreland et al. 2001). In
castrated animals, testosterone and 5α-dihydro-
testosterone administration restored the erectile
response and NOS expression in the penis
(Armagan et al. 2006; Baba et al. 2000a,
2000b). Within the follow-up data of the
Massachusetts Male Aging Study, total testos-
terone declined 0.8%/year (Feldman et al.
2002), whereas both free and albumin-bound
testosterone declined about 1.4–2%/year
(Feldman et al. 2002; Vermeulen et al. 1991).
In our previous study (Hwang et al. 2007), we
found a significant association between low
levels of serum calculated free testosterone
(cFT), bioavailable testosterone, and severity of
ED in middle-aged and aged males in Taiwan. 
Accumulated evidence supports the associ-
ation between ED and cardiovascular risk fac-
tors such as hypertension and hyperlipidemia,
as well as cardiovascular disease (Billups 2005).
Arsenic exposure has been reported to damage
peripheral vessels and cause black foot disease
(Ch’i and Blackwell 1968). Arsenic exposure
has also been correlated with cardiovascular
disease such as atherosclerosis (Wang CH et al.
2007; Wang YH et al. 2007; Wu et al. 2006).
Zarazua et al. (2006) reported that one possi-
ble explanation for the correlation between
arsenic exposure and cardiovascular disease is
that arsenic exposure is associated with the
reduction of NOS activity, which is important
in mediating relaxation of the vascular smooth
muscle. As mentioned above, NO also plays a
critical role in penile erection. However, few
studies have discussed the relationship between
arsenic exposure and ED. Therefore, our spe-
ciﬁc aim was to evaluate whether arsenic expo-
sure would increase the risk of ED in males
after adjusting for conventional risk factors.
We used questionnaires from the International
Index of Erectile Function (IIEF-5) (Rosen
et al. 1997) to measure the level of erectile
function. To our knowledge, this is the first
study to investigate the association between
ED and arsenic exposure in humans. 
Materials and Methods
Study subjects. A total of 8,102 residents from
18 villages in four townships were interviewed
and recruited as the study cohort during
1991–1994. In 1996, 5,146 subjects from the
original cohort, who were still alive and for
whom complete information was available for
contact address and arsenic levels in well water,
were sent letters inviting them to participate in
a health examination during 1997–1998;
1,318 cohort members participated (Wu et al.
2006). Because of a limited budget for the
present study, we sent invitation letters to a
random sample of 300 males ≥ 50 years of age
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BACKGROUND: Erectile dysfunction (ED) has a profound impact on the quality of life of many men.
Many risk factors are associated with ED, such as aging, sex hormone levels, hypertension, cardio-
vascular diseases, and diabetes mellitus. Arsenic exposure could damage peripheral vessels and
increase the risk of cardiovascular disease. However, the relationship between arsenic exposure and
ED has seldom been evaluated.
OBJECTIVES: In this study we aimed to investigate whether exposure to arsenic enhances the risk of ED.
METHODS: We recruited 177 males ≥ 50 years of age through health examinations conducted in
three hospitals in Taiwan. We used a questionnaire (International Index of Erectile Function-5) to
measure the level of erectile function. Sex hormones, including total testosterone and sex hormone–
binding globulin, were determined by radioimmunoassay. We used another standardized question-
naire to collect background and behavioral information (e.g., cigarette smoking; alcohol, tea, or cof-
fee drinking; and physical activity). 
RESULTS: The prevalence of ED was greater in the arsenic-endemic area (83.3%) than in the non–
arsenic-endemic area (66.7%). Subjects with arsenic exposure > 50 ppb had a signiﬁcantly higher
risk of developing ED than those with exposure ≤ 50 ppb, after adjusting for age, cigarette smok-
ing, diabetes mellitus, hypertension, and cardiovascular disease [odds ratio (OR) = 3.4]. Results also
showed that the risk of developing severe ED was drastically enhanced by arsenic exposure (OR =
7.5), after adjusting for free testosterone and traditional risk factors of ED.
CONCLUSIONS: Results suggested that chronic arsenic exposure has a negative impact on erectile
function. 
KEY WORDS: arsenic exposure, calculated free testosterone, erectile dysfunction, sex hormone, total
testosterone. Environ Health Perspect 116:532–536 (2008). doi:10.1289/ehp.10930 available via
http://dx.doi.org/ [Online 16 January 2008]from the 1,318 subjects, asking them to attend
a health screening in Lotung Poh-Ai Hospital
in 2003. From this group, we recruited
66 males ≥ 50 years of age who lived in a con-
ﬁrmed arsenic-endemic area of Lanyang Basin
in Taiwan; the details of arsenic exposure for
these subjects have been reported previously
(Chiou et al. 1997). 
The second group, representing a non–
arsenic-endemic area, was made up of 111
males ≥ 50 years of age who were recruited
through health examinations in Taipei Wan-
Fang Hospital and Taipei Medical University
Hospital in 2003.
Using a standardized self-completed ques-
tionnaire, we collected information on demo-
graphic characteristics (age, marital status,
occupation, and education), lifestyle factors
(cigarette smoking; alcohol, tea, or coffee
drinking; and physical activity), and disease
record. We used the IIEF-5 to measure the
level of erectile function. 
Participants who failed to answer the
question on ED or took hormone medication
(supplementation or deprivation) were
excluded from this study. Using IIEF-5
scores, we assigned all study subjects to ED
case (n = 129) or control (n = 48) groups. 
This study was approved by the
Institutional Review Board for human
subjects of Taipei Medical University. Each
subject provided written informed consent
prior to the study. 
Deﬁnition of erectile function. The maxi-
mum score on the IIEF-5 is 25. IIEF-5 scores
are characterized as follows: > 21, healthy with-
out ED; 12–21, mild ED; 8–11, moderate ED;
and ≤ 7, severe ED. 
Hormone measurement. Nonfasting blood
samples (8 mL) were drawn by venipuncture
from each study subject during health screen-
ing in 2003. All blood samples were collected
at 0800–1200 hours and then centrifuged at
3,000 rpm. Serum was stored at –20°C until
analysis. Total testosterone and sex hormone-
binding globulin (SHBG) were determined by
radioimmunoassay. cFT was determined by
total testosterone, albumin, and SHBG, using
the method of the International Society for
the Study of the Aging Male (2007). Serum
levels of total testosterone > 11 nmol/L and
cFT > 0.23 nmol/L were recognized as normal
(Morales et al. 2004).
Arsenic in well water and arsenic exposure.
Well water samples, collected during the home
interview, were immediately acidified with
hydrochloric acid and then stored at –20°C
until analysis. Using hydride generation com-
bined with ﬂame atomic absorption spectrom-
etry, as described previously (Chiou et al.
1997, 2001), we determined the arsenic con-
centration in the samples. Arsenic concentra-
tions in well water ranged from undetectable
(< 0.15 ppb) to 3.59 × 103 ppb. 
Statistical analyses. All data were analyzed
using SAS software (version 8.1; SAS Institute
Inc., Cary, NC, USA), and were considered
statistically signiﬁcant at p < 0.05. We assessed
statistical signiﬁcance using the chi-square test
for categorical variables and by analysis of vari-
ance (ANOVA) for continuous variables. After
completing the ANOVA and ﬁnding an effect
(rejected the null), we used Duncan’s post hoc
test to determine which groups were signifi-
cantly different from each other. Multivariable
logistic regression analyses were employed to
estimate odds ratios (ORs) and 95% confi-
dence intervals (CIs). We used models I–III to
study the relationships between ED and
arsenic exposure, testosterone, and free testos-
terone, respectively, adjusting for age, smoking,
diabetes mellitus, hypertension, and cardio-
vascular disease. Model IV was used to investi-
gate the relationship between ED and arsenic
exposure, adjusting for age, free testosterone,
smoking, diabetes mellitus, hypertension, and
cardiovascular disease. The same methodology
was applied to explore the relationship between
severe ED and arsenic exposure.
Results
The characteristics of study subjects from
arsenic-endemic and non–arsenic-endemic areas
are shown in Table 1. We found no signiﬁcant
difference in the distributions of age, hyperten-
sion, diabetes mellitus, and cardiovascular dis-
ease between study subjects from these two
areas. The average ages were 67.8 and 67.4 years
in the arsenic-endemic and non–arsenic-
endemic areas, respectively. The percentage of
cigarette smoking was significantly higher in
subjects from the arsenic-endemic area than in
those from the non–arsenic-endemic area.
Interestingly, the prevalence of ED was greater
in the arsenic-endemic area (83.3%) than in the
non–arsenic-endemic area (66.7%). 
The safe level for arsenic in drinking water
of 10 ppb, set by the U.S. Environmental
Protection Agency (2007), was based on esti-
mation of cancer risk. However, Wang YH
et al. (2007) observed a marked age- and sex-
adjusted OR of 3.3 for the development of
carotid atherosclerosis among subjects in a
high-arsenic exposure group who drank well
water containing > 50 ppb arsenic; the risk of
carotid atherosclerosis was not significant
among the group with arsenic exposures of
10–50 ppb. Therefore, we classified subjects
into two groups: arsenic exposure > 50 ppb
and ≤ 50 pp. Each group was further divided
into three subgroups according to IIEF-5
scores (i.e., > 21, 8–21, and < 8) in order to
investigate the relationship between sex hor-
mone, arsenic exposure, and ED. As shown in
Table 2, significantly lower levels of testos-
terone or free testosterone were observed in
Arsenic exposure and erectile dysfunction
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Table 1. Characteristics [no. (%)] of study subjects from arsenic-endemic and non–arsenic-endemic areas.
Arsenic-endemic areaa Non–arsenic-endemic area p-Valueb
Age (years)
< 60 9 (13.6) 22 (19.8) 0.295
≥ 60 57 (86.4) 89 (80.2)
Cigarette smoking 47 (72.3) 55 (49.6) 0.003
Diabetes mellitus 4 (6.1) 17 (15.3) 0.066
Hypertension 15 (22.7) 38 (34.2) 0.106
Cardiovascular disease 6 (13.6) 16 (14.4) 0.900
ED 55 (83.3) 74 (66.7) 0.016
aThe average duration of arsenic exposure was 42 years. bDetermined by chi-square test. 
Table 2. Sex hormone levels (mean ± SD) of study subjects categorized by erectile function and arsenic exposure.
ED status
Arsenic exposure Normal  Moderate/mild  Severe  p-Value Total
(ppb) (n = 48) (n = 49) (n = 77) for trend  (n = 174) p-Valuea
Testosterone (nmol/L) ≤ 50b  19.28 ± 7.21c 17.50 ± 4.28cd 16.03 ± 5.28d 0.01 17.55 ± 5.85
> 50 16.74 ± 4.19 15.57 ± 2.96 14.46 ± 5.16 0.22 15.04 ± 4.64 0.009
Free testosterone (nmol/L) ≤ 50b  0.42 ± 0.17c 0.40 ± 0.13cd 0.33 ± 0.17d 0.01 0.38 ± 0.16
> 50 0.39 ± 0.11 0.34 ± 0.09 0.28 ± 0.14 0.03 0.31 ± 0.13 0.003
SHBG (nmol/L) ≤ 50 33.53 ± 15.74 31.25 ± 14.21 37.31 ± 17.03 0.26 34.20 ± 15.86
> 50 28.71 ± 11.57 31.29 ± 11.34 41.79 ± 19.17 0.03 37.61 ± 17.50 0.23
ED status: normal, IIEF > 21; moderate/mild, IIEF = 8–21; severe, IIEF ≤ 7.
aCompared with ≤ 50 ppb arsenic exposure. bDuncan’s post hoc test was used to determine which groups were signiﬁcantly different from each other after completing an ANOVA in
which an effect (rejected the null) was found. c,dDifferent letters indicate signiﬁcant difference; that is, c vs. d represents signiﬁcant difference, but c vs. cd or cd vs. d represent no signiﬁ-
cant difference). severe ED cases compared with healthy con-
trols. Moreover, both arsenic exposure groups
(≤ 50 ppb and > 50 ppb) showed marked lin-
ear trends of free testosterone across different
severities of ED. However, in the case of testos-
terone, this occurred only in the group with
arsenic exposure ≤ 50 ppb. Without consider-
ing ED, we found lower average levels of
testosterone and free testosterone in subjects
with arsenic exposure > 50 ppb. The average
level of SHBG was not signiﬁcantly different
between subjects with or without arsenic expo-
sure. We observed a signiﬁcant linear trend of
SHBG across different severities of ED only in
subjects with arsenic exposure > 50 ppb. 
To further clarify the relationships between
ED and testosterone, free testosterone, and
arsenic exposure, we adjusted for traditional
risk factors (e.g., age, smoking, diabetes melli-
tus, hypertension, cardiovascular disease) in
models I–III (Table 3). Only subjects with
arsenic exposure > 50 ppb (model I) or free
testosterone < 0.23 nmol/L (model III) pos-
sessed signiﬁcant risk of ED. For arsenic expo-
sure > 50 ppb in model I, OR = 3.4 (95% CI,
1.1–10.3); for free testosterone < 0.23 nmol/L
in model III, OR = 4.8 (95% CI, 1.3–18.0).
We found no significant risk of ED among
subjects with testosterone < 11 nmol/L in
model II. Because free testosterone < 0.23
nmol/L was an important risk factor of ED in
model III, we adjusted for free testosterone in
model IV to derive a more apparent relation-
ship between arsenic exposure and ED. After
adjusting for serum free testosterone and tradi-
tional risk factors of ED, arsenic exposure still
enhanced the risk of developing ED (OR =
3.0; 95% CI, 1.0–9.2) in model IV. We
observed a signiﬁcant positive trend between
age and ED in all models. Moreover, study
subjects > 70 years of age had the highest risk
of developing ED (OR = 6.0–7.0). As shown
in Table 4, we used the same methodology to
obtain the ORs of severe ED among subjects
with arsenic exposure > 50 ppb. In model IV
(Table 4), we observed a drastically enhanced
OR (7.5; 95% CI, 1.8–30.9) for severe ED in
subjects with arsenic exposure > 50 ppb after
adjusting for age, free testosterone, diabetes
mellitus, and cardiovascular disease. Other
than arsenic exposure, the risk factors for
severe ED in model IV included age
> 70 years (OR = 30.9; 95% CI, 5.2–182.1),
abnormal serum free testosterone level (OR =
4.7; 95% CI, 1.2–18.9), diabetes mellitus
(OR = 5.5; 95% CI, 1.2–24.2), and cardio-
vascular disease (OR = 1.0; 95% CI,
1.0–26.8). We used the current WHO drink-
ing water guideline of 10 ppb (WHO 2006)
as a cut point to analyze the data again. The
OR of abnormal erectile function among sub-
jects with arsenic exposure > 10 ppb was 1.9
(95% CI, 0.7–5.3), which is not statistically
signiﬁcant after adjusting for age, free testos-
terone, smoking, diabetes mellitus, hyper-
tension, and cardiovascular disease (data not
shown). This indicates that there was no sig-
nificant risk of abnormal erectile function
among subjects with arsenic exposure
> 10 ppb. However, for severe ED we
observed a significant OR of 4.0 (95% CI,
1.2–13.6) in subjects with arsenic exposure
> 10 ppb after adjusting for age, free testos-
terone, smoking, diabetes mellitus, hyper-
tension, and cardiovascular disease (data not
Hsieh et al.
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Table 4. Multivariate-adjusted ORs and 95% CIs in subjects with severe ED (IIEF ≤ 7) compared with those with normal erectile function.
Model I Model II Model III Model IV
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age (years)
< 60 1.0 1.0 1.0 1.0
60–70 4.9 (1.0–24.0)* 4.5 (1.0–20.6)* 4.3 (0.9–20.7) 4.8 (0.9–25.4)
≥ 70 35.9 (6.5–197.5)# 27.1 (5.4–134.8)# 22.1 (4.3–114.4)# 30.9 (5.2–182.1)#
p for trend: < 0.001 p for trend: < 0.001 p for trend: < 0.001 p for trend: < 0.001
Testosterone < 11 (nmol/L) 2.4 (0.7–7.8)
Free testosterone < 0.23 (nmol/L) 4.9 (1.3–18.9)** 4.7 (1.2–18.9)**
Arsenic exposure (ppb)
≤ 50 1.0 1.0
> 50 7.7 (2.0–30.0)# 7.5 (1.8–30.9)**
Cigarette smoking 1.2 (0.4–3.0) 1.4 (0.6–3.7) 1.4 (0.5–3.5) 1.2 (0.4–3.2)
Diabetes mellitus 5.9 (1.3–27.22)** 3.8 (1.0–15.2) 3.7 (0.9–14.5) 5.5 (1.2–24.2)**
Hypertension 0.5 (0.2–1.5) 0.4 (0.1–1.1) 0.4 (0.1–1.2) 0.4 (0.1–1.4)
Cardiovascular disease 6.5 (1.3–32.1)** 4.4 (1.0–19.4)* 4.2 (0.9–19.3) 5.3 (1.0–26.8)**
Models show relationship between severe ED and arsenic exposure (model I), severe ED and testosterone (model II), severe ED and free testosterone (model III), and severe ED and arsenic
exposure, adjusting for free testosterone (model IV).
*p = 0.05. **p < 0.05. #p < 0.005. 
Table 3. Multivariate-adjusted ORs and 95% CIs in subjects with ED (IIEF ≤ 21) compared with those with normal erectile function.
Model I Model II Model III Model IV
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age (years)
< 60 1.0 1.0 1.0 1.0
60–70 1.7 (0.6–4.7) 1.9 (0.7–5.0) 1.7 (0.6–4.6) 1.6 (0.6–4.4)
≥ 70 7.0 (2.4–20.6)# 7.0 (2.4–20.7)# 6.0 (2.0–18.1)# 6.1 (2.0–18.4)#
p for trend: < 0.001 p for trend: < 0.001 p for trend: < 0.001 p for trend: < 0.001
Testosterone < 11 (nmol/L) 1.5 (0.5–4.5)
Free testosterone < 0.23 (nmol/L) 4.8 (1.3–18.0)** 4.3 (1.1–16.7)**
Arsenic exposure (ppb)
≤ 50 1.0 1.0
> 50 3.4 (1.1–10.3)** 3.0 (1.0–9.2)*
Cigarette smoking 1.2 (0.5–2.5) 1.3 (0.6–2.8) 1.3 (0.6–2.9) 1.2 (0.6–2.7)
Diabetes mellitus 3.0 (0.9–10.6) 2.5 (0.7–8.5) 2.7 (0.8–9.3) 3.2 (0.9–11.0)
Hypertension 0.5 (0.2–1.3) 0.4 (0.2–1.1) 0.4 (0.2–1.0) 0.5 (0.2–1.2)
Cardiovascular disease 3.6 (0.9–14.0) 3.1 (0.8–11.6) 3.1 (0.8–12.2) 3.4 (0.8–13.4)
Models show relationship between ED and arsenic exposure (model I), ED and testosterone (model II), ED and free testosterone (model III), and ED and arsenic exposure, adjusting for
free testosterone (model IV). 
*p = 0.05. **p < 0.05. #p < 0.005. Arsenic exposure and erectile dysfunction
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shown). The results showed that the cut point
of 50 ppb for arsenic exposure revealed a
stronger effect of arsenic in ED than when
10 ppb was used as a cut point.
Discussion
In the present study, the prevalence of ED in
arsenic-endemic and non–arsenic-endemic
areas was 83.3% and 66.7%, respectively
(Table 1). Ansong et al. (2000) used a self-
administered survey to study 5,198 randomly
selected men 50–76 years of age living in four
rural counties in central New York State.
They found age-speciﬁc prevalence of ED of
26.0%, 34.9%, 46.9%, 57.8%, and 69.4%
among men 50–54, 55–59, 60–64, 65–69,
and 70–76 years of age, respectively. In a
population-based sample of 50- to 75-year-
old Finnish men, Shiri et al. (2003) estimated
the overall prevalence of ED to be 76.5%.
The prevalence of ED increased from 67%
for men 50 years of age to 89% for those
75 years of age. The studies noted above indi-
cated that ED is a highly prevalent disorder
among men > 50 years of age, and the
prevalence of ED increased with advancing
age. In the present study, age distribution
(mean ± SD) was not significantly different
between subjects from the arsenic-endemic
area (67.77 ± 6.76) and the non–arsenic-
endemic area (67.42 ± 8.70), but we observed
a greater prevalence of ED in the arsenic-
endemic area, suggesting that arsenic may
play a role of developing ED. 
We observed a lower prevalence of dia-
betes mellitus and hypertension in study sub-
jects from the arsenic-endemic area than in
those from the non–arsenic-endemic area
(Table 1), but this was not statistically signiﬁ-
cant. Because the age distribution was similar
in subjects from these two areas, the differ-
ence in prevalence of diabetes mellitus and
hypertension between these two areas may
have been caused by health-examination bias.
However, even with a health-examination
bias, the prevalence of ED was drastically
higher in study subjects from the arsenic-
endemic area compared with those from the
non–arsenic-endemic area. This indicates a
limited inﬂuence of this potential bias regard-
ing the observation of a high prevalence of
ED in the arsenic-endemic area. 
We observed a significant association
between serum testosterone concentration,
free testosterone concentration, and the
severity of ED in the group with arsenic
exposure < 50 ppb (Table 2). Interestingly,
the average levels of free testosterone and
testosterone were significantly lower in the
subjects with arsenic exposure > 50 ppb com-
pared with the < 50-ppb arsenic group. The
data suggest that arsenic was strongly associ-
ated with a lower proportion of free fraction,
bioavailable testosterone or total testosterone
in circulating blood. Previous studies (Kim
1999; Martínez-Jabaloyas et al. 2006) have
supported the theory that sex hormones,
especially free testosterone, is associated with
sexual function. Therefore, arsenic probably
increases the risk of ED through reducing the
level of free testosterone. Data from a rat
model indicated that arsenic has a suppressive
influence on spermatogenesis and on
gonadotropin and testosterone release (Sarkar
et al. 2003). However, the actual mecha-
nism(s) by which arsenic impairs male repro-
ductive function remains unclear.
Age, diabetes mellitus, cigarette smoking,
hypertension, sex hormone, and cardio-
vascular disease have been reported to be
associated with ED. In the present study, two
risk factors of ED, diabetes mellitus and
cardiovascular disease, reached statistical sig-
niﬁcance only in the subjects with severe ED.
After adjustment for age, free testosterone,
diabetes mellitus, cigarette smoking, hyper-
tension, and cardiovascular disease, the
increased risk of ED was still found in the
subjects with arsenic exposure > 50 ppb
(Tables 3 and 4). Therefore, arsenic may also
inﬂuence erectile function via non–hormone-
dependent pathway. Oxidative stress has
been suggested to be a major cause of male
reproductive failure. Indeed, some studies
suggested that toxicity resulting from chronic
arsenic exposure was caused by oxidative
stress (Liu et al. 2001; Maiti and Chatterjee
2001; Ramanathan et al. 2002, 2003; Santra
et al. 2000). Alterations in neural and
impaired penile vascular systems were
believed to be mainly responsible for ED
rates that approached 75% in some reports
(Benet and Melman 1995; Hakim and
Goldstein 1996). NO, derived from vascular
endothelial and neural sources, played a criti-
cal role in the early steps of the normal cas-
cade of the penile vasculature and the
relaxation of cavernous smooth muscle
(Andersson and Wagner 1995; Burnett et al.
1992; Moreland et al. 2001). The presenceof
oxygen free radicals inactivated NO and
reduced its physiologic impact. Direct inacti-
vation of NO, largely by superoxide anions,
may be involved in producing impaired cav-
ernosal relaxation(Katusic 1996). 
Conclusion
The present study suggests that chronic
arsenic exposure has a negative impact on
erectile function. The potential pathways of
arsenic exposure leading to ED include the
inhibition of the sex hormone level, or reduc-
tion of NOS activity to impair the functions
of penile smooth muscle and blood vessels.
Future work, especially with a larger sample,
could further elucidate the interaction of
arsenic exposure–, sex hormone–, and oxida-
tive stress–related factors on the risk of ED. 
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